Welcome to our dedicated page for Krystal Biotech news (Ticker: KRYS), a resource for investors and traders seeking the latest updates and insights on Krystal Biotech stock.
Krystal Biotech, Inc. (KRYS) is a leader in redosable gene therapies targeting rare dermatological conditions and respiratory diseases through its proprietary HSV-1 delivery platform. This page aggregates official press releases, clinical trial updates, and regulatory developments directly from the company.
Investors and researchers can monitor progress across four key areas: dermatology (including VYJUVEK commercialization), oncology (KB707 cytokine therapy), respiratory (inhaled genetic medicines), and aesthetic medicine through subsidiary Jeune Aesthetics. All content is sourced from verified corporate communications.
Bookmark this page for real-time updates on FDA submissions, partnership announcements, and financial results. Our curation ensures you never miss critical developments in KRYS's mission to transform genetic medicine delivery.
On April 23, 2023, at the ARVO Annual Meeting, Krystal Biotech (NASDAQ: KRYS) presented promising data on the compassionate use of its gene therapy B-VEC for treating dystrophic epidermolysis bullosa (DEB) patients with ocular complications. The therapy, administered to a patient with recurrent cicatrizing conjunctivitis, showed significant results: full corneal re-epithelization within three months and improved visual acuity from hand motion to 20/40 at seven months. No drug-related adverse events were reported, underscoring the safety of B-VEC. With ocular complications affecting over half of DEB patients, this innovative treatment may address an urgent need in this underserved population, prompting the company to engage with regulatory authorities for further exploration of B-VEC’s applications.
Krystal Biotech (NASDAQ: KRYS) announced the upcoming presentation of new clinical data regarding the compassionate use of B-VEC for a patient with dystrophic epidermolysis bullosa (DEB) experiencing recurrent cicatrizing conjunctivitis. This presentation will occur during the ARVO 2023 Annual Meeting from April 23-27, 2023, in New Orleans, LA. The presentation, titled 'Topical beremagene geperpavec (B-VEC) for the treatment of recurrent cicatrizing conjunctivitis in a patient with DEB', will be delivered by Alfonso L. Sabater, M.D., PhD of the University of Miami Health System on April 23 from 12:00 PM to 1:45 PM CST.
Attendees can view the poster at the conference, and additional materials will be available online at the Company's website following the event.
Krystal Biotech (NASDAQ: KRYS) appointed Catherine Mazzacco to its Board of Directors. Her extensive background in the pharmaceutical industry, including roles at LEO Pharma and GE HealthCare, is expected to enhance the company's strategic objectives. CEO Krish S. Krishnan emphasized the importance of her experience in guiding Krystal's evolution as it advances its genetic medicines pipeline for rare diseases. Mazzacco expressed enthusiasm for contributing to the company's commercialization efforts and pipeline progression, aiming to transform lives with innovative treatments.
Krystal Biotech, Inc. (NASDAQ: KRYS) announced its participation in the 43rd Annual TD Cowen Health Care Conference in Boston from March 6-8, 2023. CEO Krish S. Krishnan will hold a fireside chat and investor meetings on March 7 at 10:30 AM ET. The presentation will be webstreamed live, with an archived version available afterward on the company’s website. Krystal Biotech focuses on developing genetic medicines for rare diseases and operates a diverse pipeline using its proprietary redosable HSV vector. Headquartered in Pittsburgh, it boasts capabilities in viral vector design and gene therapy manufacturing.
FAQ
What is the current stock price of Krystal Biotech (KRYS)?
What is the market cap of Krystal Biotech (KRYS)?
